Sinopharm Group Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Wanyong Lian

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3.7yrs
Gemiddelde ambtstermijn bestuur	4.2yrs

Recente managementupdates

Recent updates

CEO

Wanyong Lian (53 yo)

less than a year

Tenure

Mr. Wanyong Lian has been the Head of the investment management department of CNPGC since February 2008. Mr. Lian has over 20 years of working experience, all of which is management experience. Mr. Lian wa...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Wanyong Lian	President & Executive Director	less than a year	geen gegevens	geen gegevens
Xiaojuan Li	Chief Financial Officer	3.7yrs	geen gegevens	geen gegevens
Yijian Wu	Secretary to the Board	5.9yrs	geen gegevens	geen gegevens

3.7yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 1099 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Wanyong Lian	President & Executive Director	less than a year	geen gegevens	geen gegevens
Qiyu Chen	Non-Executive Vice Chairman	14.5yrs	geen gegevens	geen gegevens
Dongjiu Li	Non-Executive Director	3.4yrs	geen gegevens	geen gegevens
Xiaohui Guan	Chief Supervisor	3.4yrs	geen gegevens	geen gegevens
Tak Lung Wu	Independent Non-Executive Director	4.2yrs	CN¥350.00k	geen gegevens
Peiyu Li	Independent Non-Executive Director	4.2yrs	CN¥350.00k	geen gegevens
Bingxiang Zhao	Non-Executive Chairman	less than a year	geen gegevens	geen gegevens
Deyong Wen	Non-Executive Director	7.2yrs	geen gegevens	geen gegevens
Fangruo Chen	Independent Non-Executive Director	5.9yrs	CN¥350.00k	geen gegevens
Rongli Feng	Non Executive Director	4.4yrs	geen gegevens	geen gegevens
Weifeng Yu	Independent Non-Executive Director	4.2yrs	CN¥350.00k	geen gegevens
Peng Wang	Non-executive Director	1.2yrs	geen gegevens	geen gegevens

4.2yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 1099 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

Sinopharm Group Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Sinopharm Group Co. Ltd. Announces Change in President

Sinopharm Group Co. Ltd. Announces Management Changes

Sinopharm Group Co. Ltd. Approves Appointment of Guo Jinhong as Chief Supervisor

Sinopharm Group Co. Ltd. Announces Retirement of Ma Ping, A Non-Executive Director

Sinopharm Group Co. Ltd. Announces Resignation of Zhuo Fumin as Independent Non-Executive Director

Sinopharm Group Co. Ltd. Approves Board Appointments

Recent updates

New minor risk - Financial position

Third quarter 2024 earnings released: EPS: CN¥0.50 (vs CN¥0.64 in 3Q 2023)

Sinopharm Group Co. Ltd. to Report Nine Months, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 21%

New minor risk - Financial position

Second quarter 2024 earnings released: EPS: CN¥0.73 (vs CN¥0.81 in 2Q 2023)

Sinopharm Group Co. Ltd. Announces Change in President

Sinopharm Group Co. Ltd. Announces Management Changes

Second quarter 2024 earnings released

Sinopharm Group Co. Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Sinopharm Group Co. Ltd. Declares Final Dividend for the Fiscal Year Ended December 31, 2023, Payable on 13 August 2024

Upcoming dividend of CN¥0.87 per share

Full year 2023 earnings released: EPS: CN¥2.91 (vs CN¥2.74 in FY 2022)

Sinopharm Group Co. Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Dividend of CN¥0.87 announced

Full year 2023 earnings released: EPS: CN¥2.91 (vs CN¥2.73 in FY 2022)

Sinopharm Group Co. Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024

Investor sentiment improves as stock rises 16%

Third quarter 2023 earnings released: EPS: CN¥0.64 (vs CN¥0.70 in 3Q 2022)

Sinopharm Group Co. Ltd. to Report Nine Months, 2023 Results on Oct 27, 2023

Sinopharm Group Co. Ltd. Approves Appointment of Guo Jinhong as Chief Supervisor

Sinopharm Group Co. Ltd. Announces Retirement of Ma Ping, A Non-Executive Director

Second quarter 2023 earnings released: EPS: CN¥0.81 (vs CN¥0.72 in 2Q 2022)

Sinopharm Group Co. Ltd. to Report First Half, 2023 Results on Aug 25, 2023

Sinopharm Group Co. Ltd. Approves Final Dividend for the Financial Year End 31 December 2022, Payable on 14 August 2023

Upcoming dividend of CN¥0.82 per share at 3.4% yield

Sinopharm Group Co. Ltd. Announces Resignation of Zhuo Fumin as Independent Non-Executive Director

Full year 2022 earnings released: EPS: CN¥2.73 (vs CN¥2.49 in FY 2021)

Sinopharm Group Co. Ltd. Approves Board Appointments

Third quarter 2022 earnings released

Sinopharm Group Co. Ltd. to Report Q3, 2022 Results on Oct 26, 2022

Second quarter 2022 earnings released

Sinopharm Group Co. Ltd. to Report First Half, 2022 Results on Aug 26, 2022

Now 22% undervalued

Now 20% undervalued

Sinopharm Group Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2021, Payable No Later Than 23 August 2022

Upcoming dividend of CN¥0.75 per share

Sinopharm Group Co. Ltd. Announces Executive Changes

Sinopharm Group Co. Ltd. Announces Resignation of Deng Jindong as Member of Audit Committee and Remuneration Committee of Board

Sinopharm Group Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 23 August 2022

Now 20% undervalued after recent price drop

Full year 2021 earnings released: EPS: CN¥2.49 (vs CN¥2.31 in FY 2020)

Sinopharm Group Co. Ltd. to Report Q1, 2022 Results on Apr 21, 2022

Sinopharm Group Co. Ltd., Annual General Meeting, Jun 23, 2022

Now 22% undervalued

Third quarter 2021 earnings released: EPS CN¥0.68 (vs CN¥0.75 in 3Q 2020)

Independent Chief Supervisor Yifang Wu has left the company

Boyu, Sinopharm Reportedly Among Bidders Shortlisted for Mundipharma China

Upcoming dividend of CN¥0.69 per share

Joint Company Secretary has left the company

Full year 2020 earnings released: EPS CN¥2.31 (vs CN¥2.11 in FY 2019)

Investor sentiment improved over the past week

Full year 2020 earnings released

Sinopharm Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 19, 2021

New 90-day low: HK$17.72

Sinopharm Group Co. Ltd. Announces Chief Financial Officer Changes

New 90-day high: HK$19.88

Sinopharm Group Co., Ltd. Announces Board Appointments

Sinopharm Group Co., Ltd. Announces Board Changes

New 90-day high: HK$19.74

Third quarter earnings released

New 90-day low: HK$16.08

Sinopharm Group Co., Ltd. to Report Nine Months, 2020 Results on Oct 22, 2020

New 90-day low: HK$17.64

Sinopharm Group Co., Ltd. Appoints Management Team

Sinopharm Group Co., Ltd. Appoints Directors

First half earnings released

New 90-day low - HK$17.90

First half earnings released